NVIDIA To $230? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts adjusted targets for HD, DUOT, CNSY, ECL, DLB, NVDA and KLAR, while maintaining their existing ratings.
Follow the latest Cerenome, Inc. (CNSY) news and market headlines alongside the live CNSY price. Stay informed on what's moving CNSY.

Wall Street analysts adjusted targets for HD, DUOT, CNSY, ECL, DLB, NVDA and KLAR, while maintaining their existing ratings.
HC Wainwright & Co. analyst Sean Lee maintains Cerenome (NASDAQ:CNSY) with a Buy and raises the price target from $1 to $7.
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial
Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.95) by 20 percent. This is a 10.68 percent decrease over losses of $(1.03) per share from the same
Cerenome (Nasdaq: CNSY) reported Q3 2026 results with $0.7M in net diagnostic revenue from its CNSide CSF assay platform. The company expanded payer coverage to ~190M covered lives including new agreements with Aetna, Medical Mutual, and others. REYOBIQ therapeutic program advanced with completed Phase 2 enrollment in recurrent glioblastoma and positive interim Phase 1 multi-dose data in leptomeningeal metastases showing no dose-limiting toxicities. However, the company reported a net loss of $8.7M and cash position of $4.9M as of September 30, 2026.
Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.
Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out today. SBC
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to CNSY, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.